Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [extended cohort]

ABSTRACT: A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [extended cohort]

PROVIDER: PRJNA671693 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [extended cohort]

Project description:Population scale sweeps of viral pathogens, such as SARS-CoV-2, require high intensity testing for effective management. However, reliable systems affording parallel testing of thousands of patients for pathogen infection have not yet been routinely employed. Here we describe “Systematic Parallel Analysis of RNA coupled to Sequencing for Covid-19 screening” (C19-SPAR-Seq), a multiplexed, readily automated platform for SARS-CoV-2 detection capable of analyzing tens of thousands of patient samples in a single instrument run. To address strict requirements for control of assay parameters and output demanded by clinical diagnostics, we employed a control-based Precision-Recall and Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of several hundred patients performed with a specificity of 100% and sensitivity of 91% on samples with low viral loads. Our study thus establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.

2021-01-24 | GSE160034 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [test cohort]

2021-01-24 | GSE160032 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [PoC cohort]

2021-01-24 | GSE160031 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [pilot cohort]

2021-01-24 | GSE160033 | GEO

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [PoC cohort]

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [PoC cohort]

| PRJNA671680 | ENA

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [test cohort]

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [test cohort]

| PRJNA671682 | ENA

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [pilot cohort]

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2 [pilot cohort]

| PRJNA671689 | ENA

A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

Project description:A Multiplexed, Next-Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2

| PRJNA671674 | ENA

Maximally-multiplexed proteome quantification platform for isotopic metabolic and chemical labeling

Project description:Quantitative proteomic platforms based on precursor intensity in mass spectrometry (MS1-level) uniquely support in vivo metabolic labeling with superior quantification accuracy but suffers from limited multiplexity (≤3-plex) and frequent missing quantities. Herein, we present a maximally-multiplexed MS1-level quantification platform that comprises new six-plex in vivo SILAC or in vitro di-ethylation with a dedicated algorithm. We demonstrate accurate and missing quantity-free quantification of highly complex samples with broad dynamic ranges. With our platform, we globally profile the proteome dynamics under the heat shock response of HeLa cells.

2020-03-19 | PXD009952 | Pride

A versatile CRISPR/Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells

Project description:CRISPR technologies have begun to revolutionize T cell therapies; however, conventional CRISPR/Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To address these challenges, we developed MEGA (Multiplexed Effector Guide Arrays), a platform for programmable and scalable regulation of the T cell transcriptome using the RNA-guided, RNA-targeting activity of CRISPR/Cas13d. MEGA enables quantitative, reversible, and massively-multiplexed gene knockdown in primary human T cells without targeting or cutting genomic DNA. Applying MEGA to a model of CAR T cell exhaustion, we robustly suppressed inhibitory receptor upregulation and uncovered paired regulators of T cell function through combinatorial CRISPR screening. We additionally implemented druggable regulation of MEGA to control CAR activation in a receptor-independent manner. Lastly, MEGA enabled multiplexed disruption of immunoregulatory metabolic pathways to enhance CAR T cell fitness and anti-tumor activity in vitro and in vivo. MEGA offers a versatile synthetic toolkit for applications in cancer immunotherapy and beyond.

2023-11-06 | GSE246823 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data